SG10202101501PA - PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS - Google Patents

PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS

Info

Publication number
SG10202101501PA
SG10202101501PA SG10202101501PA SG10202101501PA SG10202101501PA SG 10202101501P A SG10202101501P A SG 10202101501PA SG 10202101501P A SG10202101501P A SG 10202101501PA SG 10202101501P A SG10202101501P A SG 10202101501PA SG 10202101501P A SG10202101501P A SG 10202101501PA
Authority
SG
Singapore
Prior art keywords
treatment
pparγ agonist
blood cancers
cancers
blood
Prior art date
Application number
SG10202101501PA
Other languages
English (en)
Inventor
Christos Mantzoros
Original Assignee
Intekrin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intekrin Therapeutics Inc filed Critical Intekrin Therapeutics Inc
Publication of SG10202101501PA publication Critical patent/SG10202101501PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10202101501PA 2016-08-18 2017-08-18 PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS SG10202101501PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662376749P 2016-08-18 2016-08-18

Publications (1)

Publication Number Publication Date
SG10202101501PA true SG10202101501PA (en) 2021-03-30

Family

ID=61197183

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202101501PA SG10202101501PA (en) 2016-08-18 2017-08-18 PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS
SG11201901320WA SG11201901320WA (en) 2016-08-18 2017-08-18 PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201901320WA SG11201901320WA (en) 2016-08-18 2017-08-18 PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS

Country Status (12)

Country Link
US (1) US20210379049A1 (https=)
EP (1) EP3500268A4 (https=)
JP (2) JP2019524888A (https=)
KR (1) KR20190064573A (https=)
CN (1) CN110461329A (https=)
AU (1) AU2017313839A1 (https=)
BR (1) BR112019003130A2 (https=)
CA (1) CA3034258A1 (https=)
EA (1) EA201990512A1 (https=)
MX (1) MX2019001979A (https=)
SG (2) SG10202101501PA (https=)
WO (1) WO2018035446A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのPPARγアゴニスト
WO2020243058A1 (en) * 2019-05-30 2020-12-03 Coherus Biosciences, Inc. Compositions and methods to treat cancer
JP2022104746A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗がん剤
JP2022104747A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗ウイルス剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3018186B1 (ja) * 1999-03-09 2000-03-13 大阪大学長 抗炎症剤、単球系細胞の増殖抑制剤
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
JP2010265216A (ja) * 2009-05-14 2010-11-25 Takeda Chem Ind Ltd 複素環化合物
KR102056756B1 (ko) * 2013-01-30 2019-12-17 인테크린 테라퓨틱스, 아이엔씨. 다발성 경화증의 치료를 위한 PPARγ 작용제
ES2866883T3 (es) * 2016-06-08 2021-10-20 Support Venture Gmbh Combinaciones farmacéuticas para el tratamiento del cáncer

Also Published As

Publication number Publication date
WO2018035446A1 (en) 2018-02-22
AU2017313839A1 (en) 2019-03-07
BR112019003130A2 (pt) 2019-05-21
EA201990512A1 (ru) 2019-08-30
CA3034258A1 (en) 2018-02-22
EP3500268A4 (en) 2020-04-15
EP3500268A1 (en) 2019-06-26
KR20190064573A (ko) 2019-06-10
JP2019524888A (ja) 2019-09-05
JP2022116304A (ja) 2022-08-09
US20210379049A1 (en) 2021-12-09
SG11201901320WA (en) 2019-03-28
CN110461329A (zh) 2019-11-15
MX2019001979A (es) 2019-09-19

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
IL266847A (en) Cancer treatment methods involving tigit-binding agents
ZA201708448B (en) Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia
IL250677A0 (en) Cancer treatment using anti-nkg2a agents
ZA201703585B (en) Combination immunotherapy approach for treatment of cancer
IL285077A (en) Compounds for the treatment of cancer
SG10201801562PA (en) Combination method for treatment of cancer
IL262005A (en) Methods of treating cancer in children
IL247267A0 (en) Methods for the treatment of vascular invasive cancers
EP3227686A4 (en) Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
SG10202101501PA (en) PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS
IL263835A (en) Exosome-guided treatment of cancer
EP3134528A4 (en) Multiple targeted rnai for the treatment of cancers
GB201717945D0 (en) Method for treatment of cancer
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
EP3389670A4 (en) METHODS OF TREATING BREAST CANCER
SG10202101500WA (en) PPARγ AGONIST FOR TREATMENT OF BONE DISORDERS
EP3102940A4 (en) Anti-metalloprotease antibody for diagnosis and treatment of cancers
HK40011080A (zh) 治疗血癌的PPARγ 激动剂
EP3125878A4 (en) Methods of treating breast cancer
HK40012509A (en) Combination immunotherapies for treatment of cancer
GB201702139D0 (en) Methods of cancer treatment
GB201622214D0 (en) treatment of cancer
GB201703857D0 (en) Treatment of cancer
GB201702565D0 (en) Treatment of cancer